All In MedTech

Device Trial Radar · NCT07224256

VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Oct 3, 2025

Primary completion

Oct 2028

Study completion Oct 2031

Sponsor

Lead sponsor
Neuralink CorpNot on our public-company list
Sponsor type
Industry
First posted
Nov 4, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irreversible speech production impairment. It is indicated for adults with neurological conditions of the central speech pathways who have impaired upper limb function. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.

Conditions

  • Tetraplegia/Tetraparesis
  • Quadriplegia
  • Cervical Spinal Cord Injury
  • Amyotrophic Lateral Sclerosis
  • Quadriplegia/Tetraplegia
  • Tetraplegic; Paralysis
  • Stroke

Interventions

  • N1 ImplantDevice

    The N1 Implant is a type of implantable brain-computer interface

  • R1 RobotDevice

    The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device-Related Adverse Events (AE)Time frame: 12 months post-implant
  2. Procedure-Related Adverse Events (AE)Time frame: 12 months post-implant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.